
## Niklas Gebauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7452011/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1789-1801.	1.2	5
2	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Advances, 2022, 6, 637-651.	2.5	15
3	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i> , <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. Haematologica, 2022, 107, 1850-1863.	1.7	17
4	Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies. Critical Reviews in Oncology/Hematology, 2022, 170, 103592.	2.0	4
5	Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. Blood Cancer Journal, 2022, 12, .	2.8	5
6	Exhaustion of tumourâ€infiltrating Tâ€cellÂreceptor repertoire diversity is an ageâ€dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma. British Journal of Haematology, 2021, 193, 138-149.	1.2	9
7	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Cancers, 2021, 13, 887.	1.7	7
8	Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3043-3050.	1.2	6
9	Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. Blood Cancer Journal, 2021, 11, 102.	2.8	28
10	Autoimmune neutropenia associated with heterozygous variant of <i>SBDS</i> gene mimicking Shwachman–Bodian–Diamond syndrome. Leukemia and Lymphoma, 2021, 62, 3047-3050.	0.6	1
11	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma. Blood Advances, 2021, 5, 5220-5225.	2.5	13
12	Comparative analysis of international prognostic indices in gray-zone lymphoma. Leukemia and Lymphoma, 2021, , 1-9.	0.6	1
13	Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. Blood Cancer Journal, 2020, 10, 63.	2.8	10
14	Impact of treatment variability and clinicopathological characteristics on survival in patients with Epsteinâ€Barrâ€Virus positive diffuse large B cell lymphoma. British Journal of Haematology, 2020, 189, 257-268.	1.2	21
15	The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 921.	1.7	15
16	Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. Cancers, 2020, 12, 873.	1.7	34
17	The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 869-873.	1.2	6
18	Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 129-136.	1.2	8

NIKLAS GEBAUER

#	Article	IF	CITATIONS
19	Favorable prognostic impact of <i>RAS</i> mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective. Leukemia and Lymphoma, 2016, 57, 226-229.	0.6	8
20	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein–Barr virus-associated diffuse large B-cell lymphoma of the elderly. Leukemia and Lymphoma, 2015, 56, 1100-1106.	0.6	43
21	<i>TP53</i> mutations are frequent events in double-hit B-cell lymphomas with <i>MYC</i> and <i>BCL2</i> but not <i>MYC</i> and <i>BCL6</i> translocations. Leukemia and Lymphoma, 2015, 56, 179-185.	0.6	57
22	MicroRNA-150 ls up-regulated in extranodal marginal zone lymphoma of MALT type. Cancer Genomics and Proteomics, 2014, 11, 51-6.	1.0	10